Drugs / Morphine
Morphine
also known as
morphine sulfate · Morphine Sulphate · morphine hydrochloride · duramorph · ITM · KADIAN · DepoDur · MS-Contin · +42 more
Other / unclassified targets OPRM1
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | MORPHINE SULFATE | — | 2010-01-25 – 2021-04-29 | fda.gov ↗ |
| Label expansion | US (FDA) | ARYMO ER | — | 2018-10-12 | fda.gov ↗ |
| Approved | US (FDA) | DURAMORPH PF | — | 1984-09-18 | fda.gov ↗ |
Trials 312 · started per year
today
US approved 1984
1
3
1
1
1
5
3
4
11
11
11
13
13
10
16
15
15
10
9
18
17
10
15
18
14
10
11
10
11
16
6
1
1984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05019638 | Mar 2021 → May 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03926559 | Apr 2019 → May 2021 | — | Augusta University | Unknown | No outcome recorded |
| Phase 0 | NCT05037812 | Mar 2019 → Mar 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02825056 | Jul 2016 → Jun 2017 | vascular disorder | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 119 trials · 1 met primary | ||||||
| Phase 1 | NCT05587998 | Aug 2022 → May 2023 | substance-related disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04448561 | Jun → Sep 2020 | substance-related disorder | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03801629 | Sep 2019 → Mar 2021 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03425084 | Jun 2018 → Feb 2020 | — | University of Southern Denmark | Completed | No outcome recorded |
| Phase 1 | NCT02824276 | Jan 2017 → Dec 2022 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02156596 | Feb 2013 → Dec 2017 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 1 | NCT01766960 | Nov 2012 → Mar 2014 | fatty liver disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT01476124 | Aug → Oct 2011 | restless legs syndrome | XenoPort, Inc. | Completed | Met primary |
| Phase 1 | NCT00802308 | Dec 2008 → Feb 2009 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00923000 | Dec 2008 → Dec 2009 | — | Tri-Service General Hospital (TSGH) | Unknown | No outcome recorded |
| Phase 1 | NCT00474799 | Jan → Feb 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00759902 | Aug → Sep 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00759915 | Aug → Sep 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00768183 | May → Jul 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00759954 | Sep → Oct 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00759759 | Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00759356 | Aug → Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00125684 | Jul 2003 → Jul 2007 | cancer | Alberta Health services | Completed | No outcome recorded |
| Phase 1 | NCT00728832 | May 2002 → Feb 2003 | — | EKR Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT06875791 | Dec 2025 → Dec 2026 expected | head and neck squamous cell carcinoma, mucositis | Fundacion Clinica Valle del Lili | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06065956 | Aug 2022 → Jun 2023 | — | Pakistan Navy Station Shifa Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04427826 | Dec 2020 → Jun 2027 expected | chronic obstructive pulmonary disease | University Hospital, Grenoble | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04138615 | Nov 2019 → Jan 2022 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04160520 | Oct 2019 → Jan 2023 | urinary system disorder | East Carolina University | Completed | No outcome recorded |
| Phase 1/2 | NCT03035578 | Dec 2017 → Jun 2018 | — | The Hospital for Sick Children | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03015246 | Dec 2016 → Jun 2020 | heroin dependence | Wayne State University | Completed | No outcome recorded |
| Phase 1/2 | NCT01975753 | May 2014 → May 2018 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 1/2 | NCT01477190 | Oct 2010 → Oct 2011 | colon carcinoma, diverticulitis, inflammatory bowel disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 1/2 | NCT01136356 | Jul 2010 → Mar 2012 | opiate dependence, opioid abuse | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00244153 | Jun 2004 → Aug 2007 | rheumatic disorder | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 1/2 | NCT00007254 | Mar 2000 → Feb 2003 | decubitus ulcer | University of Kansas | Completed | No outcome recorded |
| Phase 234 trials · 2 met primary · 3 missed | ||||||
| Phase 2 | NCT07201987 | Jan 2027 → Jan 2028 expected | — | Ganesh M. Shankar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06837857 | Apr 2025 → Jul 2029 expected | chronic pain syndrome | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06716749 | Dec 2024 → May 2025 | osteoarthritis, knee | Carilion Clinic | Completed | No outcome recorded |
| Phase 2 | NCT05800834 | Sep 2023 → Mar 2024 | breast cancer, head and neck cancer | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05367336 | Aug 2022 → Feb 2025 | qualitative platelet defect | Corewell Health South | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05017246 | Jan 2022 → Jul 2024 | uterine corpus leiomyoma | Washington University School of Medicine | Terminated | Met primary Stop: Enrollment |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05463367 | Jan 2021 → Jun 2025 overdue | chronic pain syndrome, opiate dependence, substance abuse | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04358133 | Dec 2020 → Oct 2022 | acute respiratory failure | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2 | NCT04582786 | Dec 2020 → Jan 2022 | — | Alaxia SAS | Unknown | No outcome recorded |
| Phase 2 | NCT03824834 | Aug 2019 → Jun 2020 | chronic obstructive pulmonary disease, interstitial lung disease | Dennis Jensen, Ph.D. | Unknown | No outcome recorded |
| Phase 2 | NCT03034382 | Jan 2016 → May 2017 | rotator cuff syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02267304 | Oct 2013 → Aug 2016 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2 | NCT01914042 | Jul 2013 → Jul 2019 | neuropathy, painful | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 2 | NCT01878006 | Jun 2013 → Apr 2017 | heroin dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT01871285 | Jun 2013 → Jul 2014 | — | BioDelivery Sciences International | Completed | Missed primary |
| Phase 2 | NCT01738100 | Sep 2012 → Dec 2016 | ST-elevation myocardial infarction | Hyeon-Cheol Gwon | Unknown | Missed primary |
| Phase 2 | NCT01906762 | Jul 2012 → Feb 2013 | urinary system disorder | Seyed Mehdi Pourafzali | Completed | No outcome recorded |
| Phase 2 | NCT00818493 | Feb → Jul 2009 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00678145 | Mar 2008 → Aug 2018 | autonomic nervous system disorder, hypoglycemia, type 1 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00712712 | Dec 2007 → Feb 2016 | cancer of unknown primary site, metastatic malignant neoplasm | Institut Bergonié | Completed | No outcome recorded |
| Phase 2 | NCT00446069 | Aug 2007 → Jun 2008 | cancer | Egalet Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00644319 | Mar 2007 → Sep 2009 | metastatic malignant neoplasm | Oxford University Hospitals NHS Trust | Unknown | No outcome recorded |
| Phase 2 | NCT00460239 | Jan 2007 → Jul 2009 | substance-related disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00494429 | May 2005 → Nov 2014 | — | John van den Anker | Completed | No outcome recorded |
| Phase 2 | NCT00142519 | Mar 2005 → Jul 2018 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00142896 | Feb → Dec 2005 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00388011 | Jan → Aug 2005 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00390312 | Sep → Nov 2001 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00020618 | Mar 2001 → Feb 2004 | cancer of unknown primary site | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00009672 | Jan 2001 → Dec 2006 | radiculopathy, sciatica | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00383682 | Jul 1997 → Apr 2003 | chronic pain syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Met primary |
| Phase 2 | NCT00000335 | Sep 1995 → Mar 1996 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000273 | Aug 1995 → Nov 2005 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT03407404 | Oct 2017 → Jun 2019 | — | Makerere University | Terminated | No outcome recorded |
| Phase 2/3 | NCT02967302 | Aug 2015 → Dec 2021 | osteoarthritis, knee | Hildrun Haibel | Unknown | No outcome recorded |
| Phase 2/3 | NCT03238430 | May 2015 → May 2019 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2/3 | NCT02030717 | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT01837446 | Jul 2011 → Jul 2012 | stomatitis | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00982891 | Mar 2010 → Jun 2012 | chronic obstructive pulmonary disease | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 349 trials · 6 met primary · 7 missed | ||||||
| Phase 3 | NCT06593665 | Sep 2024 → Dec 2026 expected | testicular cancer | Indiana University | Recruiting | No outcome recorded |
| Phase 3 | NCT06349668 | Apr 2024 → Oct 2027 expected | congenital anomaly of kidney and urinary tract, kidney benign neoplasm, kidney cancer, ureter benign neoplasm +3 | Hans Bahlmann | Recruiting | No outcome recorded |
| Phase 3 | NCT05236647 | Mar 2022 → Jan 2025 | — | University Hospital, Akershus | Completed | No outcome recorded |
| Phase 3 | NCT04429516 | Dec 2020 → Mar 2023 | idiopathic pulmonary fibrosis | Royal Brompton & Harefield NHS Foundation Trust | Completed | Met primary |
| Phase 3 | NCT04188418 | Oct 2020 → Aug 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | Missed primary |
| Phase 3 | NCT04455802 | Oct 2020 → May 2021 | neonatal abstinence syndrome | Women and Infants Hospital of Rhode Island | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04497831 | Sep 2020 → Sep 2022 | idiopathic pulmonary fibrosis | Medical University of Gdansk | Unknown | No outcome recorded |
| Phase 3 | NCT03948464 | Dec 2019 → Jun 2020 | substance-related disorder | M. Eugenia Socias | Terminated | No outcome recorded |
| Phase 3 | NCT03678792 | Nov 2019 → Sep 2020 | opiate dependence, substance withdrawal syndrome | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 3 | NCT03933397 | Aug 2019 → May 2022 | sickle cell disease | Duke University | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT03618082 | Jun 2019 → May 2022 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 3 | NCT03967327 | Apr 2019 → Dec 2020 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03537612 | Jun 2018 → Apr 2022 | scoliosis | Dr. Jean A. Ouellet, MD, FRCSC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03580187 | Jun 2018 → Apr 2020 | — | University Hospital, Mahdia | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03513445 | Jun 2018 → Mar 2022 | intervertebral disk degenerative disorder, lumbar disk disease, spondylolisthesis | University of Minnesota | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03429400 | Apr 2018 → May 2019 | — | West-Ward Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT03257319 | Sep 2017 → Jul 2022 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT02720822 | Aug 2016 → Dec 2019 | chronic obstructive pulmonary disease | Flinders University | Completed | Missed primary |
| Phase 3 | NCT03127800 | May 2016 → Nov 2017 | obstructive sleep apnea syndrome | Papworth Hospital NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02455362 | May 2015 → Dec 2017 | chronic obstructive pulmonary disease | Flinders University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02591017 | Feb 2015 → Jul 2017 | — | University Hospital, Basel, Switzerland | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02868944 | Aug 2014 → Jan 2017 | — | Reims University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02540070 | Aug 2014 → Dec 2017 | osteoarthritis, knee | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02173756 | Jun 2014 → Sep 2017 | cancer | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 3 | NCT02028923 | Apr 2014 → Jul 2016 | chronic ulcer of skin | Institut Curie | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01825993 | Apr 2013 → Apr 2015 | sigmoid neoplasm | Corporacion Parc Tauli | Unknown | No outcome recorded |
| Phase 3 | NCT01680939 | May 2012 → Dec 2013 | obstructive sleep apnea syndrome | Hamilton Health Sciences Corporation | Unknown | Met primary |
| Phase 3 | NCT02264821 | Feb 2012 → Aug 2014 | — | Dr Madeleine Wilwerth | Completed | No outcome recorded |
| Phase 3 | NCT01186445 | Jan 2011 → Dec 2016 | acute myocardial infarction | French Cardiology Society | Completed | Missed primary |
| Phase 3 | NCT01280331 | Jan → Apr 2011 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01367418 | Sep 2010 → Mar 2012 | prostate cancer | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT01123551 | Jun 2010 → Jul 2014 | — | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT01055015 | Feb → Dec 2010 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03365817 | Feb 2009 → Dec 2014 | chronic pain syndrome, substance-related disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT00560183 | Nov 2007 → Apr 2008 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00415597 | Dec 2006 → Mar 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00737997 | Dec 2006 → Dec 2007 | scoliosis | The Hospital for Sick Children | Completed | Missed primary |
| Phase 3 | NCT00420992 | Dec 2006 → Nov 2007 | chronic pain syndrome, osteoarthritis | Pfizer | Completed | Met primary |
| Phase 3 | NCT00390039 | May → Sep 2006 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00287326 | Jan → Jun 2006 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 3 | NCT00219921 | Sep 2005 → Feb 2007 | — | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00266539 | Apr 2004 → Apr 2005 | — | Alza Corporation | Completed | Met primary |
| Phase 3 | NCT00264485 | Mar 2004 → Apr 2005 | — | Alza Corporation | Completed | Met primary |
| Phase 3 | NCT00213200 | Jul 2003 → Jun 2005 | — | The Hospital for Sick Children | Completed | Met primary |
| Phase 3 | NCT00201539 | Apr 2002 → Nov 2006 | cancer | Norwegian University of Science and Technology | Completed | Missed primary |
| Phase 3 | NCT00003687 | Jun 1998 → Sep 2001 | cancer of unknown primary site, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +3 | NCIC Clinical Trials Group | Completed | Missed primary |
| Phase 3 | NCT00004390 | Feb 1995 → ? | postherpetic neuralgia | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 3 | NCT00410540 | ? → May 2001 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 4100 trials · 6 met primary · 6 missed | ||||||
| Phase 4 | NCT07288528 | Apr 2026 → Apr 2029 expected | hypersensitivity reaction disease | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07560501 | Apr → Dec 2026 expected | — | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07377630 | Mar 2026 → Mar 2027 expected | pregnancy disorder | Gaslini Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07851870 | Feb → Mar 2026 | — | Universitas Indonesia | Completed | No outcome recorded |
| Phase 4 | NCT07472959 | Feb → May 2026 overdue | cardiac valvular defect | Istanbul University - Cerrahpasa | Recruiting | No outcome recorded |
| Phase 4 | NCT06797973 | Jul 2025 → May 2027 expected | — | Anne Juul Wikkelsø | Recruiting | No outcome recorded |
| Phase 4 | NCT06935708 | Apr 2025 → Oct 2026 expected | colorectal carcinoma | Meri Mirceta | Recruiting | No outcome recorded |
| Phase 4 | NCT06881563 | Mar 2025 → Jul 2026 overdue | colorectal cancer | Meri Mirceta | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06666985 | Dec 2024 → Jun 2026 overdue | — | First Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT06511232 | Aug 2024 → Jul 2027 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07386353 | May 2024 → Jul 2026 overdue | — | Hospital Central do Funchal | Recruiting | No outcome recorded |
| Phase 4 | NCT05905367 | Jan 2024 → Dec 2025 | substance-related disorder | Pouya Azar | Completed | No outcome recorded |
| Phase 4 | NCT07008443 | Jan 2024 → Apr 2025 | — | Alzahraa Ahmed Abbas | Completed | No outcome recorded |
| Phase 4 | NCT06113497 | Nov 2023 → Oct 2024 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05920642 | Sep 2023 → Jul 2025 | — | University Hospital Ostrava | Completed | No outcome recorded |
| Phase 4 | NCT05742958 | Jun → Sep 2023 | — | Cukurova University | Unknown | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT07516717 | Jan 2023 → Jun 2024 | — | Hospital Universitario de Caracas | Completed | No outcome recorded |
| Phase 4 | NCT07839273 | Sep 2022 → Sep 2023 | congenital heart defects, multiple types, myocardial disorder | Baskent University | Completed | No outcome recorded |
| Phase 4 | NCT04527393 | May 2022 → Jan 2024 | — | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT05217160 | May 2021 → May 2022 overdue | — | The Metis Foundation | Recruiting | No outcome recorded |
| Phase 4 | NCT04755712 | Mar 2021 → Oct 2022 | — | Ramsay Santé | Completed | Missed primary |
| Phase 4 | NCT04752033 | Mar 2021 → Feb 2023 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05281081 | Jan → Aug 2021 | — | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT05659823 | Nov 2020 → Nov 2021 | — | Conrad Arnfinn Bjørshol | Completed | No outcome recorded |
| Phase 4 | NCT04298853 | Jun 2020 → Oct 2021 | neonatal abstinence syndrome | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT04388111 | May 2020 → Apr 2021 | arthropathy | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04017442 | Oct 2019 → Aug 2023 | postpartum depression, pregnancy disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT05259098 | Oct 2019 → Jun 2020 | chronic pain syndrome | Hospital Central do Funchal | Completed | No outcome recorded |
| Phase 4 | NCT03843281 | May 2019 → Oct 2020 | — | Bruno Minotti | Completed | No outcome recorded |
| Phase 4 | NCT03853694 | Mar 2019 → Jan 2020 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 4 | NCT03761277 | Jan 2019 → Dec 2021 | bone pain, periodic, chronic pain syndrome, neuropathy, painful | MedtronicNeuro | Completed | No outcome recorded |
| Phase 4 | NCT03693404 | Dec 2018 → Jun 2021 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04342130 | Apr 2018 → Apr 2019 | chronic pain syndrome | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT03451695 | Apr 2018 → Dec 2020 | chronic pain syndrome | B.P. Koirala Institute of Health Sciences | Completed | Missed primary |
| Phase 4 | NCT03386630 | Mar 2018 → Jun 2019 | — | Fundación Pública Andaluza Progreso y Salud | Completed | No outcome recorded |
| Phase 4 | NCT03434951 | Nov 2017 → Sep 2019 | neuropathy, painful | South Carelia Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03007121 | Apr 2017 → Dec 2018 | — | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT03875274 | Apr → Dec 2017 | — | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02929147 | Nov 2016 → Nov 2017 | supratentorial cancer | Istanbul University | Unknown | No outcome recorded |
| Phase 4 | NCT03013075 | Nov 2016 → Dec 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT02967172 | Oct 2016 → Sep 2018 | ankle defects short stature, neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02741076 | Sep 2016 → Apr 2018 | opiate dependence, opioid abuse | Member Companies of the Opioid PMR Consortium | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02924974 | Sep 2016 → May 2018 | prostate disorder | Maasstad Hospital | Completed | Met primary |
| Phase 4 | NCT02734940 | Jul 2016 → Feb 2017 | heart disorder | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 4 | NCT03675646 | Mar 2016 → Jun 2017 | neuropathy, painful | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT02848729 | Feb → Mar 2016 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 4 | NCT02627950 | Dec 2015 → Oct 2018 | acute myocardial infarction | University of Luebeck | Completed | No outcome recorded |
| Phase 4 | NCT02641301 | Dec 2015 → Dec 2016 | — | Hopital Lariboisière | Unknown | No outcome recorded |
| Phase 4 | NCT02600715 | Nov 2015 → Jun 2017 | interstitial cystitis, overactive bladder | Edgar LeClaire, MD | Completed | No outcome recorded |
| Phase 4 | NCT02530151 | Nov 2015 → May 2017 | — | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02793947 | May 2015 → Aug 2016 | neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02869321 | May 2015 → May 2018 | upper aerodigestive tract neoplasm | Central Hospital, Nancy, France | Completed | No outcome recorded |
| Phase 4 | NCT02101554 | Apr 2015 → Jun 2019 | — | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT02913469 | Dec 2014 → Aug 2020 | ST-elevation myocardial infarction | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 4 | NCT02279628 | Jul 2014 → Dec 2016 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 4 | NCT02026687 | Mar 2014 → Apr 2016 | female reproductive organ cancer | Lena Nilsson | Completed | Met primary |
| Phase 4 | NCT01898052 | Oct 2012 → Feb 2014 | — | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT01667445 | Sep 2012 → Sep 2014 | osteoarthritis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 4 | NCT01536964 | Apr 2012 → Mar 2013 | cardiovascular disorder | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01566253 | Mar → Dec 2012 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| Phase 4 | NCT01509638 | Mar → Oct 2012 | — | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 4 | NCT02046772 | Mar 2012 → Mar 2014 | hemorrhoid | Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias | Completed | No outcome recorded |
| Phase 4 | NCT02677532 | Dec 2011 → Nov 2013 | — | University of Genova | Completed | No outcome recorded |
| Phase 4 | NCT01465984 | Nov 2011 → Sep 2012 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01465191 | Nov 2011 → May 2014 | — | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01304212 | Apr 2011 → Feb 2014 | — | Jose Antonio Bernia Gil | Completed | No outcome recorded |
| Phase 4 | NCT01322360 | Apr 2011 → Apr 2012 | — | Roxane Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT02467556 | Mar 2011 → May 2014 | complex regional pain syndrome type 1 | Helsinki University Central Hospital | Completed | Met primary |
| Phase 4 | NCT02620631 | Mar 2011 → Feb 2014 | — | Stony Brook University | Unknown | Met primary |
| Phase 4 | NCT01318187 | Jan → Mar 2011 | urolithiasis | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT01422291 | Jan → Jul 2011 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT01245244 | Oct 2010 → Sep 2012 | pain agnosia | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01560767 | Oct 2010 → Jul 2011 | osteoarthritis, knee | University of Warwick | Completed | No outcome recorded |
| Phase 4 | NCT01211431 | Sep 2010 → Oct 2012 | — | Nîmes University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01234272 | Aug 2010 → Jan 2011 | gastric cancer | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01179191 | Aug 2010 → Apr 2011 | — | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT01312415 | Aug 2010 → Jun 2011 | — | Cork University Hospital | Unknown | Met primary |
| Phase 4 | NCT01079754 | Mar 2010 → Dec 2011 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT00934661 | Jan 2010 → Mar 2013 | — | Wake Forest University | Terminated | No outcome recorded |
| Phase 4 | NCT00895531 | Dec 2009 → Dec 2012 | osteoarthritis, knee | University of Louisville | Terminated | Missed primary |
| Phase 4 | NCT00878371 | May 2009 → Feb 2013 | thoracic aortic aneurysm | Nova Scotia Health Authority | Completed | Missed primary |
| Phase 4 | NCT00880607 | Dec 2008 → Apr 2011 | scoliosis | University of Colorado, Denver | Completed | Missed primary |
| Phase 4 | NCT00783016 | Oct 2008 → Feb 2011 | appendicitis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00737737 | Aug 2008 → Sep 2013 | chronic pain syndrome, osteoarthritis | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 4 | NCT00681174 | Jul 2008 → Nov 2010 | — | University of Parma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00901628 | Apr 2008 → Mar 2009 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01322191 | Apr 2008 → Nov 2010 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 4 | NCT00640042 | Mar → Nov 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00562627 | Nov 2007 → Jun 2009 | osteoarthritis, knee | Asker & Baerum Hospital | Completed | Met primary |
| Phase 4 | NCT00772187 | Oct 2007 → Sep 2009 | pain agnosia | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT00270322 | Jan 2006 → Mar 2007 | neuropathy, painful, osteoarthritis | Rambam Health Care Campus | Terminated | No outcome recorded |
| Phase 4 | NCT00155376 | Sep 2005 | liver disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00155233 | Jan 2005 → ? | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00158873 | Sep 2004 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00477061 | Jan 2004 → Mar 2005 | appendicitis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00378937 | Jan 2004 → Feb 2006 | cancer of unknown primary site | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00803114 | Mar 2002 → Nov 2004 | — | Mount Sinai Hospital, Canada | Completed | Missed primary |
| Phase 4 | NCT01112540 | — | — | Akdeniz University | Completed | No outcome recorded |
| Phase 4 | NCT00231517 | — | epidermolysis bullosa | Institute of Child Health | Completed | No outcome recorded |
| Phase not applicable88 trials · 5 met primary · 7 missed | ||||||
| — | NCT07803133 | Sep 2026 → Sep 2027 expected | — | Erzincan Binali Yildirim Universitesi | Not yet recruiting | No outcome recorded |
| — | NCT07231926 | Dec 2025 → Jul 2026 | — | Ataturk University | Completed | No outcome recorded |
| — | NCT07232108 | Dec 2025 → Jun 2026 overdue | — | Ataturk University | Recruiting | No outcome recorded |
| — | NCT07842861 | Dec 2025 → Jun 2026 | — | Cairo University | Completed | No outcome recorded |
| — | NCT07201272 | Oct 2025 → Apr 2026 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07126483 | Aug 2025 → Jan 2026 | — | Ondokuz Mayıs University | Completed | Missed primary |
| — | NCT07023679 | Jun 2025 → Jun 2029 expected | acute myocardial infarction | The Second Hospital of Anhui Medical University | Recruiting | No outcome recorded |
| — | NCT06990893 | Jun 2025 → Oct 2026 expected | — | Anqing Municipal Hospital | Recruiting | No outcome recorded |
| — | NCT06947135 | May 2025 → Jun 2026 overdue | acute myocardial infarction | The Second Hospital of Anhui Medical University | Recruiting | No outcome recorded |
| — | NCT06837506 | Feb → Aug 2025 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
| — | NCT06820190 | Feb 2025 → Dec 2026 expected | idiopathic scoliosis | Tanta University | Recruiting | No outcome recorded |
| — | NCT06761989 | Jan 2025 → Dec 2026 expected | — | Seoul National University Hospital | Recruiting | Met primary |
| — | NCT06409689 | Jun 2024 → Jun 2025 overdue | — | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT06240390 | May → Aug 2024 | neuropathy, painful | Universidad Europea de Canarias | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT06331143 | Mar 2024 → Jan 2026 | idiopathic scoliosis | Tanta University | Completed | No outcome recorded |
| — | NCT05908851 | Nov 2023 → Nov 2024 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| — | NCT07023497 | Jul 2023 → Jul 2026 overdue | — | University of Ioannina | Recruiting | No outcome recorded |
| — | NCT07012590 | May 2023 → Jul 2024 | — | Kafrelsheikh University | Completed | No outcome recorded |
| — | NCT06681805 | Jan 2023 → Sep 2024 | — | Kafrelsheikh University | Completed | No outcome recorded |
| — | NCT05738759 | May 2022 → Jul 2024 | lumbar disk disease | Queen Savang Vadhana Memorial Hospital, Thailand | Unknown | No outcome recorded |
| — | NCT06630520 | Mar → Jun 2022 | — | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT05322603 | Mar → Aug 2022 | — | Petrovsky National Research Centre of Surgery | Completed | No outcome recorded |
| — | NCT05117034 | Feb 2022 → May 2025 overdue | neuropathy, painful | Tel-Aviv Sourasky Medical Center | Active not recruiting | No outcome recorded |
| — | NCT04672382 | Jul 2021 → May 2022 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT04729049 | Feb 2021 → Jun 2022 | spondylolisthesis, vertebral column disorder | AUSL Romagna Rimini | Completed | No outcome recorded |
| — | NCT04700007 | Jan → Dec 2021 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT04445636 | Jun → Dec 2020 | — | Cairo University | Completed | No outcome recorded |
| — | NCT04402411 | Jun → Sep 2020 | urinary bladder cancer | National Cancer Institute, Egypt | Unknown | No outcome recorded |
| — | NCT05331781 | Jan 2020 → Jan 2021 | — | Sohag University | Completed | No outcome recorded |
| — | NCT05393414 | Nov 2019 → Mar 2020 | — | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT04079673 | Oct 2019 → Sep 2021 | — | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT03715517 | Oct 2018 → Jul 2031 expected | liver cancer | University of Manitoba | Recruiting | No outcome recorded |
| — | NCT03664622 | Sep 2018 → Dec 2019 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05379374 | Aug 2018 → Jan 2020 | — | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT03379987 | Jan 2018 → Jul 2019 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT03365115 | Jan 2018 → Jan 2019 | osteoarthritis, knee | Keimyung University Dongsan Medical Center | Unknown | Met primary |
| — | NCT05248724 | Aug 2017 → Sep 2020 | — | Castilla-La Mancha Health Service | Completed | No outcome recorded |
| — | NCT03232957 | Aug 2017 → Feb 2019 | osteoarthritis, knee | Mahidol University | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT02990910 | Nov 2016 → Feb 2017 | — | Children's Hospital of Fudan University | Completed | Met primary |
| — | NCT02880800 | Aug 2016 → Aug 2017 | neuropathy, painful | Mount Sinai Hospital, Canada | Unknown | No outcome recorded |
| — | NCT05853263 | Mar 2016 → Jul 2020 | congenital heart disease | Erasmus Medical Center | Completed | No outcome recorded |
| — | NCT02801838 | Feb 2016 → Feb 2017 | — | Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil | Completed | No outcome recorded |
| — | NCT02605187 | Nov 2015 → May 2017 | — | Stanford University | Completed | No outcome recorded |
| — | NCT02531165 | Sep 2015 → Feb 2018 | acute myocardial infarction | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| — | NCT02469077 | Aug 2015 → Sep 2019 | chronic pain syndrome | Vanderbilt University Medical Center | Completed | Mixed |
| — | NCT03010540 | Jul 2015 → Nov 2016 | subacute delirium | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT02440399 | Jul 2015 → May 2017 | — | HaEmek Medical Center, Israel | Completed | Missed primary |
| — | NCT02458742 | Jun 2015 → Aug 2016 | — | Mahidol University | Completed | No outcome recorded |
| — | NCT02430818 | Apr 2015 → Sep 2017 | — | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01984463 | Feb → May 2014 | — | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| — | NCT01991275 | Nov 2013 → Jun 2014 | prostate neoplasm | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01997788 | Aug → Oct 2013 | renal cell carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02064894 | Jul 2013 → Jun 2015 | musculoskeletal system disorder | St. Justine's Hospital | Completed | Missed primary |
| — | NCT01794689 | May 2013 → Jan 2018 | — | Johns Hopkins University | Completed | Met primary |
| — | NCT01690780 | Sep 2012 → Feb 2014 | — | Naveen Poonai | Completed | Missed primary |
| — | NCT01917045 | Jan 2012 → Mar 2013 | — | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT01511627 | Jan → Jul 2012 | — | University of Saskatchewan | Withdrawn | No outcome recorded |
| — | NCT01977898 | Nov 2011 → Mar 2019 | cerebrospinal fluid leak, headache disorder | Northwestern University | Completed | Missed primary |
| — | NCT01296334 | Feb → Sep 2011 | — | mads u werner | Completed | Missed primary |
| — | NCT00955877 | Mar 2010 → Jan 2015 | spastic cerebral palsy | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT01749826 | Jan 2010 → Jul 2013 | — | Stanford University | Terminated | No outcome recorded |
| — | NCT00874172 | Oct 2009 → Oct 2012 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT05831761 | Sep 2009 → Oct 2011 | — | University Medical Centre Ljubljana | Completed | Met primary |
| — | NCT00910208 | Apr 2009 → Jun 2010 | — | Albert Einstein College of Medicine | Completed | Mixed |
| — | NCT00849719 | Apr 2009 → Apr 2010 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00726830 | Mar 2009 → Sep 2010 | cancer of unknown primary site, central nervous system neoplasm, leukemia, lymphoproliferative syndrome +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01602640 | Jan 2009 → Feb 2012 | respiratory failure | Clínica de Los Andes IPS | Completed | No outcome recorded |
| — | NCT00839787 | Dec 2008 → Dec 2009 | — | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01541124 | Aug 2008 → Jun 2011 | chronic pain syndrome | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT00456638 | Apr 2008 | — | Drexel University College of Medicine | Withdrawn | No outcome recorded |
| — | NCT01366313 | Sep 2007 → Mar 2011 | — | Procare Riaya Hospital | Completed | No outcome recorded |
| — | NCT00553553 | Sep 2007 → May 2008 | liver disorder | St Vincent's University Hospital, Ireland | Unknown | No outcome recorded |
| — | NCT00504283 | Feb → Oct 2007 | nephrolithiasis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00994539 | Jan → Feb 2007 | — | Roxane Laboratories | Completed | No outcome recorded |
| — | NCT00994383 | Jan 2007 | — | Roxane Laboratories | Completed | No outcome recorded |
| — | NCT00335517 | Jun 2006 → Sep 2010 | — | University of Rochester | Completed | No outcome recorded |
| — | NCT00306020 | Jan 2006 → Jun 2012 | ulcer disease | Soroka University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00256347 | Mar 2005 → Dec 2006 | — | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00293969 | Mar 2005 → Jan 2006 | — | Montefiore Medical Center | Completed | No outcome recorded |
| — | NCT00184938 | Jan 2005 → ? | ischemic disease | Radboud University Medical Center | Suspended | No outcome recorded |
| — | NCT00199316 | Jan → Nov 2005 | — | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT00487084 | Aug 2004 → Sep 2008 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT00636415 | Jun 2004 → Jul 2005 | — | Federal University of São Paulo | Completed | Missed primary |
| — | NCT00200590 | Dec 2003 → Jul 2006 | — | Nantes University Hospital | Terminated | No outcome recorded |
| — | NCT00695045 | Jul 2003 → Jan 2007 | neuropathy, painful, osteoarthritis, knee | University College Hospital Galway | Completed | No outcome recorded |
| — | NCT01513564 | Jan 2001 → Dec 2003 | spondylolisthesis | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| — | NCT00004696 | Aug 1994 → Jul 1998 | — | Seattle Children's Hospital | Completed | No outcome recorded |
| Comparator or background therapy734 trials | ||||||
| Phase 0 | NCT06854211 Comparator | Jul 2026 → Jan 2027 expected | obstructive sleep apnea syndrome, substance-related disorder | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06617949 Comparator | Jan 2025 → Dec 2027 expected | substance-related disorder | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT06621849 Comparator | Sep 2024 → May 2025 | neuropathy, painful | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT06387303 Comparator | Aug 2024 → May 2026 overdue | — | University of Virginia | Recruiting | No outcome recorded |
| Phase 0 | NCT05150756 Comparator | Jan → Jul 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Show all 734 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 25
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Tonix Pharmaceuticals, Inc. | Results Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting tonixpharma.com ↗
Data demonstrate a substantial and persistent health burden associated with prescribed opioid use among adults with fibromyalgia |
| 2026-04-24 | Indivior Inc. | Results Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder indivior.com ↗
Patients with higher MOUD coverage (>80% of time on MOUD) experienced less non-fatal and fatal overdose compared to those with lower MOUD coverage (<80%). |
| 2024-12-05 | Glycyx Therapeutics | Results Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It glycyx.com ↗
The article, titled “Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma” , is available in the latest issue of the Journal for ImmunoTherapy of Cancer (JITC) . |
| 2023-02-14 | Trevena Inc. | Results Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY trevena.com ↗
The results of the study demonstrated that oliceridine and morphine differed in their pharmacodynamics with a more rapid onset and offset of respiratory depression for oliceridine and a smaller magnitude of respiratory depression over time. |
| 2022-10-24 | Trevena Inc. | Results Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting trevena.com ↗
These data add to our prior published work with oliceridine, and continue to suggest that it may provide a reduced impact on ventilatory function as compared to IV morphine. |
| 2022-04-20 | Trevena Inc. | Results Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects trevena.com ↗
These data suggest that OLINVYK, a new chemical entity, may offer a more favorable respiratory safety profile when compared to IV morphine. |
| 2022-03-31 | Trevena Inc. | Results Trevena Reports Fourth Quarter and Full Year 2021 Results trevena.com ↗
Topline data of OLINVYK vs IV morphine in high-risk subjects demonstrates statistically significant benefit in lowering respiratory depression |
| 2021-08-10 | Trevena Inc. | Results Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy trevena.com ↗
The findings suggest that under equianalgesic conditions, patients receiving OLINVYK were less likely to experience adverse events (AEs) compared to patients treated with morphine. |
| 2021-05-03 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection amphastar.com ↗ |
| 2020-12-18 | Avenue Therapeutics, Inc. | Results Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network avenuetx.com ↗
Compared to other common opioid compounds, tramadol had significantly lower rates of NMU, non-oral routes of administration such as snorting or injecting, and diversion, suggesting a lower abuse potential. |
| 2020-10-05 | Trevena Inc. | Results Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting trevena.com ↗
OLINVYK demonstrated an overall lower incidence of respiratory safety events (RSEs) (12.8% - 13.8%) compared with IV morphine (22.8% - 23.4%) in Phase 3 randomized controlled trials (RCTS) in orthopedic and plastic surgeries. |
| 2020-09-21 | Trevena Inc. | Results Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting trevena.com ↗
OLINVYK was associated with a higher probability of analgesia than respiratory depression, while the reverse was true for morphine. |
| 2020-06-05 | Avenue Therapeutics, Inc. | Results Avenue Therapeutics Announces Publications in Peer-Reviewed Journals avenuetx.com ↗
The results of the study demonstrated that IV tramadol was statistically superior to placebo and comparable to IV morphine for the primary and all key secondary efficacy outcomes. |
| 2019-06-03 | Avenue Therapeutics, Inc. | Results Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain avenuetx.com ↗
In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine. |
| 2018-11-14 | Talphera, Inc | Results AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting talphera.com ↗
Over the first five hours, patient dosing in each treatment arm suggests that a single 15 mcg or 30 mcg tablet has the equivalent analgesic effect to approximately 2.5 mg or 5 mg of IV morphine, respectively. |
| 2016-12-19 | Lannett Company, Inc. | Regulatory Lannett Announces Supplemental Approval For Morphine Sulfate Oral Solution CII, 20 mg/mL investorroom.com ↗
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate Oral Solution CII, color and flavor added, 20 mg/mL. |
| 2016-10-27 | Trevena Inc. | Results Trevena Announces Highlights from Recent Presentations trevena.com ↗
Two oral podium presentations reviewed results from Phase 2 studies of oliceridine, including comparisons of oliceridine to morphine. |
| 2015-06-24 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval for Pyridostigmine Bromide Tablets zyduslife.com ↗
The Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets. |
| 2014-11-17 | Trevena Inc. | Results Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain trevena.com ↗
Over the 48 hour study period, TRV130 3 mg every 3 hours showed statistically superior analgesic efficacy compared to morphine. |
| 2014-06-24 | Trevena Inc. | Results Results of Phase 1b Clinical Trial Comparing Trevena’s TRV130 to Morphine Published in the Journal Pain trevena.com ↗
These data suggest that TRV130 may reduce patients’ pain more effectively, act more quickly, produce less severe GI side effects and reduce the risk of respiratory depression compared to existing opioids, resulting in an improved margin of safety for dosing. |
| 2012-11-15 | Talphera, Inc | Results AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain talphera.com ↗ |
| 2012-08-08 | Perrigo Company | Regulatory Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution perrigo.com ↗
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for morphine sulfate 100ml/5% oral solution. |
| 2011-06-24 | Lannett Company, Inc. | Regulatory Lannett Receives Fda Approval For Morphine Sulfate Oral Solution Nda Lannett Receives Fda Approval For Morphine Sulfate Oral Solution Nda investorroom.com ↗
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s 505(b)(2) New Drug Application (NDA) for Morphine Sulfate Oral Solution on June 23, 2011. |
| 2011-06-06 | Lannett Company, Inc. | Regulatory Lannett Announces Revised Fda Pdufa Date For Morphine Sulfate Oral Solution Nda Lannett Announces Revised Fda Pdufa Date For Morphine Sulfate Oral Solution Nda investorroom.com ↗
“With a revised PDUFA date in 17 days, we are preparing for the re-launch of our Morphine Sulfate Oral Solution product, if approved,” said Arthur Bedrosian, president and chief executive officer of Lannett. |
| 2001-01-31 | Egalet Ltd | Results Proof of concept for an improved twice-daily controlled-release formulation of morphine. egalet.com ↗
Egalet a/s has demonstrated proof of concept for an improved twice-daily controlled-release formulation of morphine. |
All press releases naming this drug 29 releases
Evidence & citations 55 cited values
Every value below carries the sentence it was read from. 1,055 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | morphine | “The current double-blind, placebo-controlled in-patient study was designed to compare the effects of intravenously delivered fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70...” PMID 17581533 ↗ Jun 2007954“All patients will be submitted to the institution's standard management: multimodal analgesia with common analgesic (dipyrone 4 to 8 g / day or paracetamol 1500 to 2250 mg /...” NCT07666178 ↗ “The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the...” NCT05163366 ↗ “Postoperative patient controlled epidural analgesia (epidural cathterer inserted into Th7-8 intervertebral space, 200 ml of 0.125% levobupivacaine, 4 mg of morphine, 0.075 mg...” NCT05831761 ↗ “Intravenous morphine bolus doses of 2.5 mg or 5 mg may be administered for breakthrough pain when CPOT remains greater than 1 or when the treating clinician judges that pain is...” NCT06727435 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made...” NCT01667445 ↗ “Preservative-free morphine hydrochloride 100 micrograms will be added to 10 mg of hyperbaric bupivacaine 0.5% and administered into the intrathecal space at the L3-L4 or L4-L5...” NCT07784192 ↗ “Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then...” NCT01526525 ↗ “To evaluate the levels of morphine in a patient's blood when morphine is given into the epidural space in the form of DepoDur® either alone or following a dose of lidocaine...” NCT00804609 ↗ “An intraoperative block of the genital branch of the genitofemoral nerve was performed in all patients in all three groups, followed by postoperative patient-controlled...” PMID 27487311 ↗ Jul 2016 |
| Known as | Actiskenan | “morphine (Actiskenan) 5-10 mg every 4-6 h for severe pain” NCT07414706 ↗ |
| Known as | Apokyn | “Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others)” NCT06240390 ↗ |
| Known as | Avinza | “We would like to learn if a medicine called "modified-release morphine sulfate" (Avinza) helps reduce Spinal Cord Injury (SCI)-related pain that has lasted a long time.” NCT00488969 ↗2“Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others)” NCT06240390 ↗ “Avinza (morphine sulfate sustained-release) capsules” NCT00782548 ↗ |
| Known as | Chlorhydrate of Morphine | “Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump.” NCT02292667 ↗ |
| Known as | DepoDur | “The primary purpose of this study is to evaluate the effects of lidocaine/epinephrine test dose administration on the PK profile of a single epidural dose of DepoDur...” NCT00728832 ↗ |
| Known as | Depolan | “Depolan (morphine), Ebixa (memantine)” NCT02467556 ↗ |
| Known as | Dimorf | “Dimorf” NCT05800834 ↗ |
| Known as | duramorph | “Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)” NCT06593665 ↗8“Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine was given for a patient 18-75 years of age” NCT05257941 ↗ “preservative free morphine (Duramorph)” NCT05506930 ↗ |
| Known as | Egalet morphine | “Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks” NCT00446069 ↗1“Single dose administration of Egalet® morphine with alcohol” NCT00802308 ↗ |
| Known as | EREM | “The primary objective was to evaluate the serum pharmacokinetic profile of a single 15-mg dose of extended-release epidural morphine (EREM) administered at the lower thoracic...” PMID 19840530 ↗ Nov 20092“Extended-release Epidural morphine (EREM) 80” NCT00955877 ↗ “Extended Release Epidural Morphine (EREM)” NCT00934661 ↗ |
| Known as | Immediate release morphine | “Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)” NCT04635852 ↗ |
| Known as | intra spinal morphine | “intra spinal morphine” NCT00695045 ↗ |
| Known as | IRM | “immediate-release morphine (IRM) as solution or tablet is most frequently used in clinical practice to treat episodic breathlessness.” NCT04635852 ↗ |
| Known as | ITM | “This randomized double-blind trial investigates the relative contributions of adductor canal block and low-dose intrathecal morphine (ITM) to postoperative analgesia and...” PMID 29315129 ↗ Feb 20186“Intrathecal morphine (ITM) and continuous wound infiltration (CWI) are two alternatives to thoracic epidural analgesia in major abdominal surgery” PMID 42403225 ↗ Jul 2026 “Erector Spinae Plane Block (ESPB) and intrathecal morphine (ITM) provide adequate postoperative (PO) analgesia.” PMID 40047853 ↗ Mar 2025 “120 mcg intrathecal morphine (ITM) will be administered to the morphine group.” NCT06076018 ↗ “Intrathecal morphine sulfate (ITM)” NCT04368364 ↗ “ITM (Intrathecal Morphine)” NCT06666985 ↗ “Intrathecal morphine (ITM)” NCT03261193 ↗ |
| Known as | IVMS | “IVMS (IV Morphine)” NCT01904071 ↗ |
| Known as | KADIAN | “a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially...” NCT00759356 ↗5“Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others)” NCT06240390 ↗ “KADIAN (morphine sulfate sustained-release) capsules” NCT00759954 ↗ “KADIAN (morphine sulfate sustained-release) capsules” NCT00782548 ↗ “KADIAN (morphine sulfate extended-release) capsules” NCT00759902 ↗ “KADIAN (morphine sulfate extended-release) capsules” NCT00759915 ↗ |
| Known as | MIR | “At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).” NCT04087317 ↗ |
| Known as | MNS075 | “Intranasal (IN) Morphine Nasal Spray (MNS075) 7.5 mg and 15 mg” NCT00390039 ↗ |
| Known as | MOR | “Patients were consented and randomized to receive, either IV ketamine (LDK) 1 mg/kg or IV morphine (MOR) 0.1 mg/kg as an infusion over 10 min.” PMID 29794277 ↗ Jan 2018 |
| Known as | Morfin | “spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age” NCT02030717 ↗ |
| Known as | Morfina cloridrato 10 mg /ml - Morphine | “Morfina cloridrato 10 mg /ml - Morphine” NCT01249872 ↗ |
| Known as | Morfini Sulfas WZF | “postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)” NCT06609993 ↗ |
| Known as | Morphin | “morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria)” NCT01084473 ↗1“Morphin” NCT00878293 ↗ |
| Known as | Morphine = morphine | “Morphine = morphine” NCT01367418 ↗ |
| Known as | morphine chlorhydrate | “Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1...” NCT02781415 ↗1“inhaled titration of morphine chlorhydrate” NCT03257319 ↗ |
| Known as | Morphine Chloride | “Drug: Morphine Chloride” NCT04700007 ↗ |
| Known as | Morphine HCl | “Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram” NCT00553553 ↗1“Drug: Morphine HCl” NCT04582786 ↗ |
| Known as | morphine hydrochloride | “Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under...” NCT05073744 ↗14“The auxiliary drug on which both experimental strategies are based is MORPHINE: Morphine hydrochloride AGUETTANT 0.1 mg/mL Solution for injection (ready-to-use ampoule) for...” NCT07076641 ↗ “Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.” NCT04700007 ↗ “morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria)” NCT01084473 ↗ “Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation” NCT05848635 ↗ “a bolus of 150 mcg / Kg of morphine hydrochloride, approximately 60 minutes before extubation” NCT02571491 ↗ “Patients are receiving Morphine hydrochloride under thoracic surgery” NCT06172920 ↗ “5 mg of morphine hydrochloride (10mg/ml Braun Medical SA Spain)” NCT05248724 ↗ “Morphine hydrochloride, remifentanil hydrochloride” NCT00553553 ↗ “Morphine hydrochloride, Spinal” NCT03434951 ↗ “Drug: Morphine hydrochloride” NCT04427826 ↗ |
| Known as | Morphine Hydrochloride Injection | “The pump is filled with a 100 mL mixture of the active comparator drug, Morphine Hydrochloride Injection, at a concentration of 0.25 mg/mL, and the same adjuvant drug,...” NCT07412223 ↗ |
| Known as | Morphine hydrochloride oral solution 2 mg/ml | “Morphine hydrochloride oral solution 2 mg/ml” NCT01245244 ↗ |
| Known as | Morphine Kalceks | “In Spinal group, 25 G or 27 G pencil point needle, depending on the preference of the anesthesiologist, will be inserted at L2-L3 or L3-L4 intervertebral space and 300 μg of...” NCT06935708 ↗1“300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.” NCT06881563 ↗ |
| Known as | Morphine special | “The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine...” NCT02026687 ↗1“Morphine special (preservative-free) injected intrathecally” NCT01281891 ↗ |
| Known as | morphine SR | “In one-third of the patients oral sustained release morphine (morphine SR) doesn't relieve dyspnea” NCT02429050 ↗ |
| Known as | morphine sulfate | “AVINZA (morphine sulfate extended-release capsules) was approved for marketing by the Food and Drug Administration (FDA) in 2002 as a once daily treatment for the relief of...” NCT00640042 ↗101“To compare the effect of prophylactic fentanyl buccal tablet (FBT), morphine sulfate, and placebo on the increase in the intensity of exertional dyspnea (0-10 point modified...” NCT04188418 ↗ “A Study to Evaluate the Effects of Epidural Lidocaine Administration on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® (Morphine Sulfate Extended-release...” NCT00804609 ↗ “Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.” NCT02101554 ↗ “A long acting comparator (slow-release morphine sulfate 45 mg) will be chosen because of its putative equianalgesic effects to the dose of hydrocodone (30 mg) selected.” NCT00314340 ↗ “Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings” NCT04859803 ↗ “comparing ketamine hydrochloride (20 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes)” PMID 38285446 ↗ Jan 2024 “morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg” NCT00994383 ↗ “standardized intravenous (IV) morphine sulfate or Sponsor-approved equivalent for postsurgical analgesia” NCT01509638 ↗ “200 µg morphine sulfate, single-dose via L3-L4, 27G Sprotte spinal needle, prior to induction.” NCT07231926 ↗ |
| Known as | Morphine sulfate (MS) Contin, Astramorph, Depodur, Duramorph, Infumorph, Kadian, MorphaBond, Arymo ER (morphine) | “Morphine sulfate (MS) Contin, Astramorph, Depodur, Duramorph, Infumorph, Kadian, MorphaBond, Arymo ER (morphine)” NCT05037812 ↗ |
| Known as | morphine sulfate extended-release liposome injection | “morphine sulfate extended-release liposome injection” NCT00895531 ↗ |
| Known as | Morphine Sulfate Injection USP | “Morphine Sulfate Injection USP” NCT05324358 ↗ |
| Known as | Morphine Sulphate | “Patients will receive a single intravenous (IV) infusion administered over 3 minutes of either ORG 28611 (SCH 900111), 0.12 mg/kg morphine sulphate, or placebo” NCT00782951 ↗16“PAciFy Cough is a multicenter, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of cough in IPF.” PMID 35236391 ↗ Mar 2022 “30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt)” NCT03078946 ↗ “Morphine group (GM): given ultrasound guided TAP-block with 20ml 0.5% bupivacaine+10mg morphine sulphate diluted in 20ml saline” PMID 28494906 ↗ Mar 2017 “Group I: (n=20) received IV 0.1mg/kg morphine sulphate (morphine sulfate ®, Misr CO Pharma).” NCT02449954 ↗ “tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily” NCT04589494 ↗ “0.125% bupivacaine HCL + Morphine sulphate 3 mg” NCT01838707 ↗ “Morphine Sulphate Controlled Release” NCT00472303 ↗ “Morphine sulphate: 50 mg/ml” NCT07733427 ↗ “Drug: Morphine sulphate” NCT00802308 ↗ “Drug: Morphine sulphate” NCT03682211 ↗ |
| Known as | Morphine sulphate 10mg/ml, Martindale Pharmaceuticals (UK) | “Morphine sulphate 10mg/ml, Martindale Pharmaceuticals (UK)” NCT02434939 ↗ |
| Known as | Morphine, Orion (ATC code: N02A A01) | “Morphine, Orion (ATC code: N02A A01)” NCT05639712 ↗ |
| Known as | MS Contin, Astramorph, Depodur, Duramorph, Infumorph, Kadian, MorphaBond, Arymo ER (morphine) | “MS Contin, Astramorph, Depodur, Duramorph, Infumorph, Kadian, MorphaBond, Arymo ER (morphine)” NCT05019638 ↗ |
| Known as | MS-Contin | “This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of morphine)-to treat pain caused by lumbar radiculopathy, or sciatica.” NCT00009672 ↗4“Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others)” NCT06240390 ↗ “* Morphine Sulfate (MS) Contin: Use as backup prn pain” NCT02219581 ↗ “MS Contin (morphine sulfate, controlled release)” NCT01380093 ↗ |
| Known as | MSIR | “Oxycodone or morphine sulfate immediate release (MSIR)” NCT02824276 ↗1“Morphine Sulfate Immediate Release (MSIR)” NCT00751478 ↗ |
| Known as | MST | “low dose (5mg) controlled release Morphine sulfate (MST) will reduce the number of coughs recorded during a 24hr period in patients with IPF.” NCT04429516 ↗ |
| Known as | MST Continus | “Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks” NCT00446069 ↗ |
| Known as | nMOR | “OBJECTIVE: To determine the predictive factors of nebulized morphine (nMOR)” PMID 36196899 ↗ Oct 2022 |
| Known as | PFMS | “The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).” NCT03761277 ↗ |
| Known as | spinal morphine | “spinal morphine” NCT03428880 ↗ |
| Known as | SROM | “Slow release oral morphine (SROM)” NCT03948464 ↗ |
| Known as | Sterop | “During the first 24 postoperative hours, analgesia will be provided via a patient-controlled analgesia (PCA) pump delivering 2 mg intravenous HCL morphine (Sterop®) boluses on demand.” NCT07568405 ↗ |
| Action | Activate | “This effect is based on an activation of peripheral opioid receptors” NCT00244153 ↗ |
| Modality | Other / unclassified | “Fentanyl HCl and morphine are narcotic pain relievers.” NCT00264485 ↗ |
| Route | Intravenous | “The current double-blind, placebo-controlled in-patient study was designed to compare the effects of intravenously delivered fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70...” PMID 17581533 ↗ Jun 2007 |
| Target | OPRM1 | “The mu-opioid receptor (OPRM1 gene)is the site of action of endogenous opioid peptides and opioid analgesic drugs like morphine.” NCT01465191 ↗ |